Singapore markets closed
Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,478.57 +0.67 (+0.01%) Dow
39,227.67 +99.87 (+0.26%) Nasdaq
17,810.81 +5.65 (+0.03%) Bitcoin USD
61,786.47 -10.95 (-0.02%) CMC Crypto 200
1,289.63 +23.48 (+1.85%)
PCVX Sep 2024 100.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 6.60 |
| Open | N/A |
| Bid | 3.00 |
| Ask | 7.90 |
| Strike | 100.00 |
| Expiry date | 2024-09-20 |
| Day's range | 8.80 - 8.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.